JP2018538367A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538367A5
JP2018538367A5 JP2018545568A JP2018545568A JP2018538367A5 JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5 JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5
Authority
JP
Japan
Prior art keywords
medicament according
treatment
heart failure
medicament
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018545568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063036 external-priority patent/WO2017091496A1/en
Publication of JP2018538367A publication Critical patent/JP2018538367A/ja
Publication of JP2018538367A5 publication Critical patent/JP2018538367A5/ja
Withdrawn legal-status Critical Current

Links

JP2018545568A 2015-11-24 2016-11-21 ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定 Withdrawn JP2018538367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
JP2018538367A JP2018538367A (ja) 2018-12-27
JP2018538367A5 true JP2018538367A5 (enExample) 2019-12-19

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545568A Withdrawn JP2018538367A (ja) 2015-11-24 2016-11-21 ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定

Country Status (13)

Country Link
US (1) US20180325869A1 (enExample)
EP (1) EP3380091A1 (enExample)
JP (1) JP2018538367A (enExample)
KR (1) KR20180081528A (enExample)
CN (1) CN108348479A (enExample)
AU (1) AU2016359463A1 (enExample)
BR (1) BR112018010155A8 (enExample)
CA (1) CA3006291A1 (enExample)
EA (1) EA201891007A1 (enExample)
IL (1) IL259468A (enExample)
MX (1) MX2018005756A (enExample)
SG (1) SG11201803816RA (enExample)
WO (1) WO2017091496A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034227B1 (ru) 2015-12-10 2020-01-20 Бристол-Майерс Сквибб Компани Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110996950B (zh) 2017-06-09 2023-04-04 百时美施贵宝公司 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
ES2964299T3 (es) 2018-11-26 2024-04-05 Bristol Myers Squibb Co Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153985A (en) * 2007-12-18 2015-04-30 Actelion Pharmaceuticals Ltd Aminotriazole derivatives as alx agonists
CN103221392B (zh) * 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
TW201348219A (zh) * 2012-05-16 2013-12-01 Actelion Pharmaceuticals Ltd 作爲alx受體激動劑之經1-(對-甲苯基)環丙基取代橋聯螺[2.4]庚烷衍生物
EA034227B1 (ru) * 2015-12-10 2020-01-20 Бристол-Майерс Сквибб Компани Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
SG11202008504SA (en) * 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists

Similar Documents

Publication Publication Date Title
JP2018538367A5 (enExample)
JP2020523327A5 (enExample)
MX2024010140A (es) Nuevos metodos.
JP2016034978A5 (enExample)
JP2016510326A5 (enExample)
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
JP2015083580A5 (enExample)
EP4335418A3 (en) Compositions and methods for treating pterygium
JP2015508749A5 (enExample)
JP2018184433A5 (enExample)
JP2018537507A5 (enExample)
JP2017532343A5 (enExample)
JP2017222722A5 (enExample)
JP2017519739A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2017517512A5 (enExample)
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
CR20220089A (es) Proteínas de fusión terapéuticas
MX389330B (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
JP2013087119A5 (enExample)
JP2018513846A5 (enExample)
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
JP2016503794A5 (ja) 疾患の治療のための医薬組成物
JP2012525422A5 (enExample)